GLUE
Monte Rosa Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -25.0% ·
share flow -15.7% ·
net new positions -20.0%
· formula
Broad distribution: falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +1 | 213.96K | $2.51M | +1 | n/a |
| Q2 2026 | 77 | -4 | 40.74M | $985.15M | +4 | −8 |
| Q1 2026 | 84 | +11 | 37.29M | $613.27M | +14 | −3 |
| Q4 2025 | 73 | -1 | 26.21M | $411.01M | +1 | −2 |
| Q3 2025 | 18 | +2 | 20.02M | $148.32M | +2 | n/a |
| Q2 2025 | 13 | +1 | 20.51M | $92.50M | +1 | n/a |
| Q1 2025 | 9 | -3 | 9.96M | $46.20M | +1 | −4 |
| Q4 2024 | 12 | +2 | 11.82M | $82.01M | +2 | n/a |
| Q3 2024 | 9 | +2 | 9.48M | $50.23M | +2 | n/a |
| Q2 2024 | 7 | n/a | 8.29M | $30.99M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 6.64M | -6.6% | $30.83M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passive) | 1.00M | -3.1% | $4.66M | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 801.26K | -25.6% | $3.72M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Marshall Wace ✦ | 371.74K | -25.6% | $1.72M | 0.0% | ▼ Trim | 3 | SEC ↗ ×3 |
| 5 | Millennium Management ✦ | 330.47K | +612.7% | $1.53M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 229.54K | New | $1.07M | 0.0% | New | 1 | SEC ↗ ×5 |
| 7 | Two Sigma Investments ✦ | 223.13K | -20.0% | $1.04M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 8 | Wellington Management ✦ | 187.73K | -15.3% | $871,072 | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 9 | Renaissance Technologies ✦ | 164.10K | -33.2% | $761,424 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| AQR Capital Management | $1.07M | 0.0% |
Exited
| Citadel Advisors | $5.40M | was 0.0% |
| Norges Bank | $3.09M | was 0.0% |
| D. E. Shaw & Co. | $486,591 | was 0.0% |
| Point72 Asset Management | $1,736 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 188 holders, 86.88M shares, $1.31B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 13 sh · $137
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
7.9% of class · View original SEC filing ↗